Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283089 | 1.00 | SLC7A5 (0.56) | SLC7A5ESR1ESR2CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL20422673 | 0.98 | SLC7A5 (0.54) | SLC7A5ESR1ESR2CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL20422675 | 0.98 | SLC7A5 (0.54) | SLC7A5ESR1ESR2CYP1A2HSD17B10 | |
| SCHEMBL15360000 | 0.83 | CYP1A2 (0.49) | SLC7A5CYP1A2HSD17B10PTGS1PKM | |
| SCHEMBL13957329 | 0.81 | CYP1A2 (0.47) | SLC7A5CYP1A2HSD17B10PTGS1PKM | |
| SCHEMBL12128833 | 0.81 | CYP1A2 (0.47) | SLC7A5CYP1A2HSD17B10PTGS1PKM | |
| SCHEMBL4208145 | 0.81 | CYP1A2 (0.47) | SLC7A5CYP1A2HSD17B10PTGS1PKM | |
| SCHEMBL8168327 | 0.81 | ESR1 (0.49) | SLC7A5ESR1ESR2ALDH1A1KIF11 | |
| Hydrochloric Acid SCHEMBL25217806 | 0.80 | CYP1A2 (0.46) | SLC7A5CYP1A2HSD17B10PTGS1PKM | |
| SCHEMBL31369948 | 0.80 | NNMT (0.47) | SLC7A5CYP1A2HSD17B10PTGS1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| EP-0313094-B1 | ANTICANCER AGENT AND REAGENT FOR OBTAINING REVERTANTS | MEIJI SEIKA KAISHA LTD. (JP) | 1993-09-01 | — | — | EP | claimed |
| EP-0313094-A2 | Anticancer agent and reagent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1989-04-26 | — | — | EP | claimed |
| JP-1110627-A | — | — | None | — | — | JP | disclosed |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | IBIO, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748449-A2 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-0313094-B1 | ANTICANCER AGENT AND REAGENT FOR OBTAINING REVERTANTS | MEIJI SEIKA KAISHA LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
| EP-0529655-A1 | 2-Piperidinecarboxylic acid derivative, oncogene suppressor and agent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| JP-H01110627-A | CARCINOSTATIC AND BACK MUTANT CELL COLLECTOR | MEIJI SEIKA KAISHA LTD | 1989-04-27 | — | — | JP | disclosed |
| EP-0313094-A2 | Anticancer agent and reagent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| EP-0313094-A2 | Anticancer agent and reagent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | SLC7A5 1802/4885ESR1 3621/4885ESR2 2553/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | SLC7A5 2476/4885ESR1 2304/4885ESR2 1598/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | SLC7A5 1047/4885ESR1 3984/4885ESR2 1854/4885 |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | MSTN, MST1R, MYOF | SLC7A5 4441/4885ESR1 1873/4885ESR2 1807/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | SLC7A5 3138/4885ESR1 2719/4885ESR2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.